Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

19.89
+1.075.69%
Pre-market: 20.010.1200+0.60%06:06 EDT
Volume:2.96M
Turnover:58.52M
Market Cap:3.87B
PE:-39.72
High:20.00
Open:18.90
Low:18.85
Close:18.82
52wk High:37.50
52wk Low:16.24
Shares:194.49M
Float Shares:91.34M
Volume Ratio:1.59
T/O Rate:3.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5008
EPS(LYR):-1.6200
ROE:-8.08%
ROA:-1.92%
PB:3.15
PE(LYR):-12.28

Loading ...

Legend Biotech (LEGN) Stock Could Be 51.2% Undervalued After Equity Raise And LB2501 Data

Simply Wall St.
·
Jun 19

Movement Alert|Legend Biotech Falls 16.02% in Regular Trading, Secondary Offering of $226 Million ADS Priced at Discount

Market Focus
·
Jun 19

BUZZ-U.S. STOCKS ON THE MOVE-Kardigan, Energy companies

Reuters
·
Jun 18

Legend Biotech falls -12.2%

TIPRANKS
·
Jun 18

BUZZ-U.S. STOCKS ON THE MOVE-Pfizer, Accenture, Kroger

Reuters
·
Jun 18

Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga_recent_news
·
Jun 18

BUZZ-Legend Biotech slides on $226 mln share sale

Reuters
·
Jun 18

BRIEF-Legend Biotech Corporation Announces Pricing Of Public Offering

Reuters
·
Jun 18

Legend Biotech - Gross Proceeds From Offering Expected to Be About $226 Mln

THOMSON REUTERS
·
Jun 18

Legend Biotech - Prices 7.7 Mln Ads Public Offering at $29.35 per Ads

THOMSON REUTERS
·
Jun 18

Stocks to Watch: Smith & Wesson, Logistic Properties of the Americas, Legend Biotech

Dow Jones
·
Jun 18

Legend Biotech ADSs Fall After Company Announces Public Offering

Dow Jones
·
Jun 18

Legend Biotech secondary offering; price range $29.35-$31.35

TIPRANKS
·
Jun 18

Legend Biotech launches USD 225 million ADS follow-on offering

Reuters
·
Jun 18

Legend Biotech Corporation Announces Proposed Public Offering

THOMSON REUTERS
·
Jun 18

Legend Biotech - Commences $225 Mln Public Offering of American Depositary Shares

THOMSON REUTERS
·
Jun 18

Legend Biotech management to meet with Oppenehimer

TIPRANKS
·
Jun 17

Legend Biotech Unveils Strong First-in-Human Data for In Vivo CAR-T LB2501 at EHA 2026

TIPRANKS
·
Jun 15

Legend Biotech says Phase 1 LB2501 in vivo CD19/CD20 CAR-T posts 100% ORR at higher dose in R/R B-cell NHL

Reuters
·
Jun 15

Legend Biotech Says In Vivo CAR-T Candidate LB2501 Delivers Early Proof-of-Concept in Lymphoma

MT Newswires Live
·
Jun 15